{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:28:07Z","timestamp":1775550487418,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12881-016-0284-4","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T11:25:41Z","timestamp":1457609141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["12\u00a0year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment"],"prefix":"10.1186","volume":"17","author":[{"given":"Orazio","family":"Gabrielli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorne A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ficcadenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Zampini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni V.","family":"Coppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"284_CR1","volume-title":"The online metabolic and molecular basis of inherited disease","author":"ES Neufeld","year":"2007","unstructured":"Neufeld ES, Muenzer J. The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The online metabolic and molecular basis of inherited disease. New York: MacGrow Hill; 2007. doi:10.1036\/ommbid.165."},{"key":"284_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123:19.","journal-title":"Pediatrics"},{"key":"284_CR3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2010","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month old boy with attenuated presymptomatic MPS I: 5-years follow up. Pediatrics. 2010;125, e183.","journal-title":"Pediatrics"},{"key":"284_CR4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","volume":"19","author":"N Wille","year":"2010","unstructured":"Wille N, Badia X, Bonsel G, Burstr\u00f6m K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19:875.","journal-title":"Qual Life Res"},{"key":"284_CR5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/glycob\/cwq088","volume":"20","author":"GV Coppa","year":"2010","unstructured":"Coppa GV, Buzzega D, Zampini L, Maccari F, Galeazzi T, Pederzoli F, et al. Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients. Glycobiology. 2010;20:1259.","journal-title":"Glycobiology"},{"key":"284_CR6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182.","journal-title":"N Engl J Med"},{"key":"284_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidoses I. Pediatrics. 2009;123:229.","journal-title":"Pediatrics"},{"issue":"Suppl","key":"284_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ker396","volume":"50","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology. 2011;50(Suppl):49\u201359.","journal-title":"Rheumatology"},{"key":"284_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90:171.","journal-title":"Mol Genet Metab"},{"key":"284_CR10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pediatrneurol.2012.08.010","volume":"47","author":"A Jurecka","year":"2012","unstructured":"Jurecka A, Marucha J, Jurkiewicz E, Rozdzynska-Swiatkowska A, Tylki-Szymanska A. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up. Pediatr Neurol. 2012;47:461.","journal-title":"Pediatr Neurol"},{"key":"284_CR11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway S, Breen C, Mercer J, Jones S, Wraith JE. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol Genet Metab. 2013;109:315.","journal-title":"Mol Genet Metab"},{"key":"284_CR12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111:1027.","journal-title":"Mol Genet Metab"},{"key":"284_CR13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:131.","journal-title":"Orphanet J Rare Dis"},{"key":"284_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10545-012-9538-2","volume":"36","author":"MH Ru De","year":"2013","unstructured":"De Ru MH, van der Tol L, van Vlies N, Bigger BW, Hollak CEM, Ijlst L, et al. Plasma and urinary levels of dermatan sulphate and heparan sulphate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J Inherit Metab Dis. 2013;36:247.","journal-title":"J Inherit Metab Dis"},{"key":"284_CR15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","volume":"114","author":"EJ Langereis","year":"2015","unstructured":"Langereis EJ, van Vlies N, Church HJ, Geskus RB, Hollak CEM, Jones SA, et al. Biomarker responses correlate with antibody status in Mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol Genet Metab. 2015;114:129.","journal-title":"Mol Genet Metab"},{"issue":"Suppl","key":"284_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/rheumatology\/ker395","volume":"50","author":"LA Clarke","year":"2011","unstructured":"Clarke LA. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology. 2011;50(Suppl):13\u20138.","journal-title":"Rheumatology"},{"key":"284_CR17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ymgme.2014.09.012","volume":"114","author":"JM Heppner","year":"2015","unstructured":"Heppner JM, Zaucke F, Clarke LA. Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in Mucopolysaccharidosi I. Mol Genet Metab. 2015;114:146.","journal-title":"Mol Genet Metab"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-016-0284-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T08:03:10Z","timestamp":1498291390000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2350\/17\/19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1186\/s12881-016-0284-4","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]},"article-number":"19"}}